Can a Two-Drug combo free CML patients from daily pills?
NCT ID NCT03610971
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This phase 2 study tests whether adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) therapy can help people with chronic myeloid leukemia (CML) stop their medication and stay in remission. The 24 participants had already tried stopping TKI once but relapsed. They will take both drugs for 12 cycles, then attempt to stop again. The main goal is to see how many remain cancer-free without treatment after one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering
New York, New York, 10021, United States
-
Duke University Hospital
Durham, North Carolina, 27710, United States
-
Emory -Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Memorial Sloan Kettering - Bergen
Montvale, New Jersey, 07645, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib (Jakafi) plus a tyrosine kinase inhibitor (imatinib, dasatinib, nilotinib, or bosutinib)
What this could lead to
If it works, this could help some CML patients stay off their daily medication for longer periods without the cancer returning.
What could go wrong
This is a small, early-phase trial with only 24 people, so results may not apply to everyone. The combination therapy may cause side effects, and many patients may still need to restart medication.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.